D

Duopharma Biotech Bhd
KLSE:DPHARMA

Watchlist Manager
Duopharma Biotech Bhd
KLSE:DPHARMA
Watchlist
Price: 1.24 MYR -0.8% Market Closed
Market Cap: 1.2B MYR
Have any thoughts about
Duopharma Biotech Bhd?
Write Note

Wall Street
Price Targets

DPHARMA Price Targets Summary
Duopharma Biotech Bhd

Wall Street analysts forecast DPHARMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DPHARMA is 1.49 MYR with a low forecast of 1.35 MYR and a high forecast of 1.63 MYR.

Lowest
Price Target
1.35 MYR
9% Upside
Average
Price Target
1.49 MYR
20% Upside
Highest
Price Target
1.63 MYR
31% Upside
Duopharma Biotech Bhd Competitors:
Price Targets
600062
China Resources Double-Crane Pharmaceutical Co Ltd
32% Upside
003090
Daewoong Co Ltd
22% Upside
DMP
Dermapharm Holding SE
30% Upside
MANKIND
Mankind Pharma Ltd
11% Upside
300765
CSPC Innovation Pharmaceutical Co Ltd
53% Upside
MARKSANS
Marksans Pharma Ltd
6% Downside
4503
Astellas Pharma Inc
27% Upside
NEU
Neuren Pharmaceuticals Ltd
126% Upside

Revenue
Forecast

Revenue Estimate
Duopharma Biotech Bhd

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's revenue is 13%. The projected CAGR for the next 3 years is 8%.

13%
Past Growth
8%
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Duopharma Biotech Bhd

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's operating income is 6%. The projected CAGR for the next 3 years is 20%.

6%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Net Income
Forecast

Net Income Estimate
Duopharma Biotech Bhd

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's net income is 5%. The projected CAGR for the next 3 years is 22%.

5%
Past Growth
22%
Estimated Growth
Estimates Accuracy
-9%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DPHARMA's stock price target?
Price Target
1.49 MYR

According to Wall Street analysts, the average 1-year price target for DPHARMA is 1.49 MYR with a low forecast of 1.35 MYR and a high forecast of 1.63 MYR.

What is Duopharma Biotech Bhd's Revenue forecast?
Projected CAGR
8%

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's revenue is 13%. The projected CAGR for the next 3 years is 8%.

What is Duopharma Biotech Bhd's Operating Income forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's operating income is 6%. The projected CAGR for the next 3 years is 20%.

What is Duopharma Biotech Bhd's Net Income forecast?
Projected CAGR
22%

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's net income is 5%. The projected CAGR for the next 3 years is 22%.

Back to Top